Craig Hallum Begins Coverage on Compass Therapeutics (NASDAQ:CMPX)

Research analysts at Craig Hallum assumed coverage on shares of Compass Therapeutics (NASDAQ:CMPX) in a report released on Friday. The brokerage set a “buy” rating and a $15.00 price target on the stock. Craig Hallum’s price target points to a potential upside of 136.59% from the stock’s previous close.

Several other analysts have also issued reports on the stock. Citigroup started coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They set an “outperform” rating for the company. Wall Street Zen lowered shares of Compass Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, February 8th. Canaccord Genuity Group set a $13.00 target price on Compass Therapeutics in a research note on Wednesday, February 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Wednesday, January 21st. Finally, Leerink Partners raised Compass Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 26th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $13.00.

Compass Therapeutics Price Performance

Shares of CMPX opened at $6.34 on Friday. Compass Therapeutics has a 1 year low of $1.33 and a 1 year high of $6.88. The firm has a market cap of $1.13 billion, a P/E ratio of -14.09 and a beta of 1.46. The stock has a 50 day simple moving average of $5.65 and a two-hundred day simple moving average of $4.47.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CMPX. Suvretta Capital Management LLC boosted its stake in shares of Compass Therapeutics by 97.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock worth $49,354,000 after buying an additional 6,951,666 shares during the last quarter. Vivo Capital LLC lifted its holdings in Compass Therapeutics by 57.9% in the third quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after acquiring an additional 3,502,000 shares during the period. Vanguard Group Inc. lifted its holdings in Compass Therapeutics by 45.6% in the third quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock valued at $24,720,000 after acquiring an additional 2,212,794 shares during the period. Adage Capital Partners GP L.L.C. boosted its position in Compass Therapeutics by 11.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock worth $11,505,000 after purchasing an additional 449,868 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Compass Therapeutics by 19.0% during the 4th quarter. Geode Capital Management LLC now owns 3,502,526 shares of the company’s stock valued at $18,813,000 after purchasing an additional 558,057 shares during the period. 68.43% of the stock is owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.